49 research outputs found

    Functionalization of Carbon Nanomaterial Surface by Doxorubicin and Antibodies to Tumor Markers

    Get PDF
    The actual task of oncology is effective treatment of cancer while causing a minimum harm to the patient. The appearance of polymer nanomaterials and technologies launched new applications and approaches of delivery and release of anticancer drugs. The goal of work was to test ultra dispersed diamonds (UDDs) and onion-like carbon (OLCs) as new vehicles for delivery of antitumor drug (doxorubicin (DOX)) and specific antibodies to tumor receptors. Stable compounds of UDDs and OLCs with DOX were obtained. As results of work, an effectiveness of functionalization was 2.94 % w/w for OLC-DOX and 2.98 % w/w for UDD-DOX. Also, there was demonstrated that UDD-DOX and OLC-DOX constructs had dose-dependent cytotoxic effect on tumor cells in the presence of trypsin. The survival of adenocarcinoma cells reduced from 52 to 28 % in case of incubation with the UDD-DOX in concentrations from 8.4–2.5 to 670–20 μg/ml and from 72 to 30 % after incubation with OLC-DOX. Simultaneously, antibodies to epidermal growth factor maintained 75 % of the functional activity and specificity after matrix-assisted pulsed laser evaporation deposition. Thus, the conclusion has been made about the prospects of selected new methods and approaches for creating an antitumor agent with capabilities targeted delivery of drugs

    Глутаровая ацидурия типа 1 у детей. Клиническое представление 46 случаев, диагностированных в России

    Get PDF
    Background. Glutaric aciduria type 1 is an autosomal recessive disease caused by mutations in the GCDH gene, which encodes the enzyme glutaryl‑CoA dehydrogenase. Metabolic crisis in type 1 glutaric aciduria is an acute life‑threatening condition that requires careful diagnosis with a number of other conditions and the immediate initiation of pathogenetic therapy.Materials and methods. Clinical manifestations, neuroimaging characteristics of the disease were studied in 46 patients with diagnosed glutaric aciduria type 1 confirmed by biochemical and molecular genetic methods. Methods: gas chromatography with mass spectrometry, tandem mass spectrometry, Sanger sequencing, chromosomal microarray analysis of the exon level.Results and discussion. A retrospective analysis of anamnestic and clinical data was carried out, and the nature and age of disease manifestation, provoking factors, a spectrum of clinical manifestations and neuroimaging data were assessed.Conclusion. How initiated treatment prevents progression of neurological symptom relief and patient adaptation. With the help of the goal, it is necessary to inform pediatricians, neurologists and neuroradiologists about this feature of the course of glutaric aciduria type 1 in order to increase the clinical alertness of this disease.Введение. Глутаровая ацидурия типа 1 – аутосомно‑рецессивное заболевание, обусловленное мутациями в гене GCDH, кодирующем фермент глутарил‑КоА дегидрогеназу. Метаболический криз при глутаровой ацидурии типа 1 – это острое жизнеугрожающее состояние, требующее тщательной дифференциальной диагностики с рядом других состояний и незамедлительного начала патогенетической терапии.Материалы и методы. Клинические проявления, нейровизуализационные характеристики болезни изучены у 46 пациентов с подтвержденным биохимическими и молекулярно‑генетическими методами диагнозом глутаровой ацидурии типа 1. Методы: газовая хроматография с масс‑спектрометрией, тандемная масс‑спектрометрия, секвенирование по Сэнгеру, хромосомный микроматричный анализ экзонного уровня.Результаты и обсуждение. Проведен ретроспективный анализ анамнестических данных, клинических, а также оценены характер и возраст манифестации болезни, провоцирующие факторы, спектр клинических проявлений и нейровизуализационные данные.Заключение. При отсутствии массового неонатального скрининга крайне важное значение имеет ранняя диагностика болезни, так как своевременно начатое лечение поможет предотвратить прогрессирование неврологической симптоматики и способствовать адаптации пациентов. С этой целью необходимо информировать врачей‑педиатров, неврологов и нейрорадиологов об особенностях протекания глутаровой ацидурии типа 1 для повышения клинической настороженности в отношении данного заболевания

    Very long-chain acyl-coenzyme A dehydrogenase deficiency

    No full text
    The paper describes a case of a baby with a severe infant form of very long-chain acyl-coenzyme A dehydrogenase deficiency, a very rare genetic disorder. The basis for the disease is a disorder of mitochondrial β-oxidation of long-chain fatty acids. Accumulation of acyl-CoA-derived fatty acids causes a toxic effect on the myocardium and cardiac conduction system, liver, skeletal muscles, and other organs. The development of hypoglycemia is typical. Treatment in the acute period involves the immediately ceased delivery of long-chain triglycerides, the provision of the body with medium-chain triglycerides, and the correction of glycemia. In our observation the baby was born at term with a satisfactory condition in a family with a poor history (the first baby had suddenly died at the age of 3,5 months). The disease manifested itself as bradyarrhythmia and cardiac arrest on day 2 of life. The clinical symptom complex also included hepatomegalia, hypoglycemic episodes, lactate acidosis, and elevated blood levels of cytolytic enzymes and creatine phosphokinase. The diagnosis was suspected on the basis of the high blood values of acylcarnitines (primarily C14:1) and verified by a molecular genetic examination. Syndrome therapy and dietotherapy resulted in the abolishment of the abnormality. At the age of 2 years of life, the infant’s physical, motor, mental, and speech development corresponded to his age although he had mild right-sided hemiparesis. Thus, timely therapy determines the favorable prognosis of the disease even in its severe infant forms
    corecore